Industry Briefs: September 17, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Almac has launched a new histone reagents catalog and custom synthesis service. Read More
The biopharmaceutical company Bionomics has acquired Eclipse Therapeutics, a stem-cell research company. Read More
Catalent Pharma Solutions and CTC Bio have agreed to provide services to South Korean pharmaceutical companies seeking to commercialize solid oral-dose and controlled-release products in the US and Europe. Read More
Haupt Pharma successfully passed inspections by FDA at four sites in Germany during the first half of 2012. Read More
Recipharm has received regulatory approval from the French health authorities to fill biotechnology products at its site in Monts, France. Read More
Sanofi’s subsidiary Genzyme has received FDA approval for a new molecular entity, Aubagio (teriflunomide), a once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis. Read More
SGS Life Science Services completed an expansion of its Fairfield, New Jersey, facility on Sept. 20, 2012. The expansion enlarges the size of the facility from 15,000 to 30,000 ft2 by adding modernized and new GMP/GLP-compliant laboratories, and increases ICH Zone 1–4 storage capacities.
West has launched B.safe, its syringe-safety system technology system. Read More
People Notes
Emisphere Technologies has appointed Alan L. Rubino as president and CEO, effective immediately. Read More
Patheon has appointed Harry Gill to senior vice-president of quality and continuous improvement. Read More
Unicep, contract packaging company, has announced new ownership with Marcus Anderson, current president, and Clint Marshall, current chief financial officer purchasing the company from its founder, John Snedden. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
